Miglustat

In the US, Miglustat (miglustat systemic) is a member of the drug class miscellaneous metabolic agents and is used to treat Gaucher Disease.

US matches:

• Miglustat

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A16AX06

CAS registry number (Chemical Abstracts Service)

0072599-27-0

Chemical Formula

C10-H21-N-O4

Molecular Weight

219

Therapeutic Category

Enzyme inhibitor

Chemical Name

(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

Foreign Names

• Miglustatum (Latin)
• Miglustat (German)
• Miglustat (French)
• Miglustat (Spanish)

Generic Names

• Miglustat (OS: USAN, BAN)
• OGT 918 (IS: OxfordGlycoSci)
• SC 48334 (IS)

Brand Names

• Zavesca
  Actelion, Austria; Actelion, Belgium; Actelion, Canada; Actelion, Switzerland; Actelion, Czech Republic; Actelion, Germany; Actelion, Denmark; Actelion, Spain; Actelion, Finland; Actelion, France; Actelion, United Kingdom; Actelion, Hungary; Actelion, Ireland; Actelion, Italy; Actelion, Japan; Actelion, Luxembourg; Actelion, Netherlands; Actelion, Norway; Actelion, Slovenia; Actelion, Slovakia; Actelion, United States; Actelion Pharmaceuticals, Sweden; Teva, Israel

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.